Nutriphos Injection

Adult dosage

A maximum of 1 to 1.5 g of total amino acids per kilogram of body weight should be administered as a drip injection daily. The infusion rate is ideally a concentration of about 10 g of total amino acids over 60 minutes, with a principle of drips of 30 to 40 drops per minute.

Children's dosage

In children, the dose and infusion speed should be adjusted accordingly.

This medication must be used according to a doctor's instructions, and should not be used arbitrarily without a prescription. It should not be used in patients with hepatic coma or those at risk of hepatic coma, severe renal impairment, or patients with azotemia. It is also safe to avoid administering it to patients with problems in nitrogen metabolism, cachexia, pulmonary edema, oliguria, or anuria. When sodium and chloride ions are included, it should not be administered to patients with hypernatremia, hyperchloremia, or alkalosis, and caution should be exercised for patients with a history of myocardial infarction. Patients with severe acidosis, congestive heart failure, edema due to sodium retention, hyperkalemia, or potassium retention should be administered with care. Patients with liver or kidney dysfunction may experience allergic reactions due to sodium bisulfite in this medication, especially asthmatic attacks, so caution is advised. Allergic reactions can rarely occur as rashes, and gastrointestinal symptoms such as nausea or vomiting, chest discomfort, palpitations, and hypertension may appear. Rapid large-volume administration can cause metabolic acidosis, so care must be taken with the rate and volume of administration. Severe adverse reactions such as chills, fever, headache, dyspnea, shock, bronchospasm, and urinary tract spasms may also occur, so immediate notification to medical personnel is required if abnormal symptoms are observed. Various metabolic disorders like metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, hypoglycemia, elevated liver enzymes, vitamin imbalances, and electrolyte imbalances can occur. Patients with impaired liver or kidney function may need periodic testing as blood urea nitrogen (BUN) levels may rise. Patients with severely impaired liver function are at risk for serum amino acid imbalance or metabolic alkalosis, hyperammonemia, and coma, so special care is needed during administration. In the case of large doses, electrolyte imbalances may occur, so periodic monitoring of electrolyte status is important, especially when used with solutions containing electrolytes. Formulations containing acetate ions can induce metabolic alkalosis in case of overdose, so strict adherence to dosing is necessary. Patients with kidney disease, lung disease, or severe heart disease must adjust dosing and speed to prevent side effects from fluid overload. Diabetic patients are at risk of fluctuations in blood sugar, so blood glucose should be monitored frequently during administration. This medication may decrease the protein-sparing effect of amino acids when used with tetracycline antibiotics, so caution is advised during co-administration. Safety in pregnant women has not been established, so it should be administered only when the therapeutic benefits outweigh the risks. In children, as liver function may be immature, doses should be reduced, and particularly in infants, frequent monitoring of blood ammonia levels is necessary due to the risk of hyperammonemia. Elderly patients, due to degraded physical function, should have their administration rate slowed and dosages reduced if necessary. This medication contains electrolytes, so care must be taken regarding electrolyte balance with large doses, and the infusion speed should be slowly adjusted to prevent side effects. The injection solution should be warmed to body temperature and prepared under sterile conditions, ensuring sterilization of injection devices. Before use, check if the solution is clear and free from any abnormalities, and do not use the solution if it is discolored or leaking. The remaining solution should be used promptly and can be refrigerated for use within 24 hours, and if crystals form, they should be appropriately heated to dissolve before use. The solution should be stored in such a way to prevent discoloration until the package is opened, and products with damaged rubber stoppers should not be used. Exact dosages should be based on the marked scale of the container, and safe storage and handling practices are essential.

Serious side effects

• Hives, severe swelling (edema), chest tightness, difficulty breathing, pallor → severe allergic reactions.
• Anaphylactic shock.
• Severe skin reactions.
• Dyspnea, respiratory arrest, shock, bronchospasm, asthma attacks.
• Symptoms related to liver dysfunction (jaundice).
• Severe neurological symptoms.
• Significantly reduced urine output, severe edema with elevated blood pressure → severe edema or urination abnormalities.

Mild side effects

• Nausea
• vomiting
• rash
• chest discomfort
• palpitations
• tachycardia
• hypertension
• chills
• fever
• headache

This medication should be stored in a sealed container to prevent air or moisture from entering, at room temperature between 1 degree and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness and prevents deterioration.

Appearance

A colorless to pale yellow transparent solution in a multi-layer film plastic container, containing an aqueous injection in a polypropylene injection container.

Package unit

250 milliliters/pack